Beth Israel Deaconess Medical Center, Inc.

Arch Development Corporation

Dana-farber-cancer Institute Inc.

The University of Chicago

Other

University of California

Massachusetts Institute of Technology

The General Hospital Corporation

The Hospital for Sick Children

The Beth Israel Hospital Association

Children's Hospital Boston

Vikas P Sukhatme

S Ananth Karumanchi

Donald W Kufe

Ralph R Weichselbaum

Dennis E Hallahan

Sharon Maynard

Jian-Guo Ren

Bruce D Hammock

Sung Hee Hwang

Zaheed Husain

Mourad Toporsian

Dipak Panigrahy

Michelle V Letarte

Junichi Hanai

Mohammad Movassaghi

Allison Gartung

Anna Fishbein

Leonard I Zon

Jenna Galloway

Ralph H Weichselbaum

Mo Motamedi

Ananth S Karumanchi

The invention provides methods for treating, suppressing, or preventing detrimental cytokine and/or lipid mediator surges that can result from a variety of different diseases, conditions, and therapeutic treatments, e.g., by inhibition of cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH).

Methods for the prevention or treatment of cytokine storm

Described herein are compounds, pharmaceutical compositions, and methods for use in reversing cancer chemoresistance.

Compounds, pharmaceutical compositions, and methods of their use in reversing cancer chemoresistance

Methods for treating cancer, e.g., in conjunction with anti-cancer therapy, like immunotherapy, and for identifying candidate therapeutic agents, by targeting ICAM4. While MDSCs in mice have been extensively characterized, their human counterparts are not well defined, and cell markers present in mice are not always usable in humans. MDSCs have been described as a heterogenous population of myeloid derived cells with immune suppressive capacity (5, 9, 40, 41). Recent renewed interest in the role of MDSC accumulation in human tumors has resulted in the increased need to define these cells better in order to target them for therapeutic intervention.

Cancer therapy targeting intercellular adhesion molecule 4 (ICAM4)

Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that alter soluble endoglin levels or biological activity.

Methods of diagnosing and treating complications of pregnancy

The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing proliferative disorders, such as cancel-, that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include monotherapy with malate, or a derivative thereof, as well as combination therapy, such as malate, or a derivative thereof, combined with another therapeutic agent, such as a malic enzyme 2 inhibitor, an antineoplastic agent, a glycolysis inhibitor, an antiangiogenic agent, an immunomodulatory agent, an antibody, or a cytokine.

Methods of treating proliferative disorders with malate or derivatives thereof

Disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1- are also disclosed herein for the treatment of pre-eclampsia or eclampsia.

Methods of treating pre-eclampsia or eclampsia

The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.

Methods and compositions for malic enzyme 2 (ME2) as a target for cancer therapy

Disclosed herein are kits for diagnosing pre-eclampsia and eclampsia or a propensity to develop pre-eclampsia or eclampsia that include agents for the detection of levels of free placental growth factor in a subject.

Kits for the diagnosis of pre-eclampsia or eclampsia

The invention features methods and compositions for treating and preventing angiogenic disorders and endothelial cells disorders using HspA12B antagonist and HspA12B agonist compounds, respectively.

Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders

Disclosed herein are methods for diagnosing or treating pregnancy related hypertensive disorders that include the use of a polypeptide or a nucleic acid encoding a polypeptide selected from the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehyrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

Nucleic acids and polypeptides useful for diagnosing complications of pregnancy

Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia. Also disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1- are also disclosed herein for the treatment of pre-eclampsia or eclampsia.

Methods of diagnosing pre-eclampsia or eclampsia

The present disclosure demonstrates the successful use of constitutive promoters operatively linked to genes encoding radiosensitizing or radioprotecting factors, administered to cells, tissues, or patients in conjunction with radiation exposure. Also disclosed are pharmacological preparations to be used to increase the levels of radiosensitizing compounds such as TNF-&#x3b1;, or radioprotective compounds such as MnSOD, in specified tissues or tumors of a subject.

Constitutive gene expression in conjunction with ionizing radiation

Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia. Also disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1&#x2014;are also disclosed herein for the treatment of pre-eclampsia or eclampsia.

Methods of treating pre-eclampsia and eclampsia

Disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin and sFlt-1 expression levels or biological activity. Also disclosed are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that increase endothelial nitric oxide synthase levels or biological activity.

Growing community of inventors

Newton, MA, United States of America

Vikas P Sukhatme